Dirui Industrial Co (300396) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was ¥350.69 million, down 60.07% year-over-year, with a net loss attributable to shareholders of ¥28.31 million, reversing a profit of ¥165.24 million in the prior year.

• Gross margin declined, and both domestic and international sales faced challenges, though international markets showed some resilience.

• The company continued to invest in R&D, launching new products and enhancing its AI-driven diagnostic capabilities.

• Management implemented reforms in sales strategy, incentives, and organizational structure to address market and operational pressures.

Financial highlights

• Operating income: ¥350.69 million, down 60.07% year-over-year.

• Net loss attributable to shareholders: ¥28.31 million, compared to a profit of ¥165.24 million last year.

• Operating cash flow: -¥8.43 million, a significant improvement from -¥287.72 million last year.

• Basic and diluted EPS: -¥0.1038, down from ¥0.6060.

• Gross margin for medical devices: 38.91%; for reagents: 60.53%.

Outlook and guidance

• The company expects continued pressure from domestic market controls and price competition but aims to leverage R&D and international expansion for recovery.

• Management is focused on increasing reagent sales volume and improving cost structure.